Harrow (NASDAQ:HROW) Stock Keeps Buy Rating at BTIG Research

BTIG Research restated their buy rating on shares of Harrow (NASDAQ:HROW) in a research report report published on Wednesday morning,Benzinga reports. They currently have a $63.00 price objective on the stock.

A number of other equities analysts have also weighed in on HROW. Zacks Research lowered shares of Harrow from a “hold” rating to a “strong sell” rating in a report on Tuesday, November 3rd. Wall Street Zen raised Harrow from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Harrow in a research note on Friday, October 16th. Finally, Leerink Partners initiated coverage on Harrow in a report on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 target price for the company. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $66.20.

Harrow Price Performance

HROW opened at $29.37 on Wednesday. The firm has a market cap of $1.10 billion, a PE ratio of -37.65 and a beta of 0.18. The stock has a 50-day moving average price of $31.15 and a 200-day moving average price of $37.67. Harrow has a 1 year low of $25.76 and a 1 year high of $54.85. The company has a debt-to-equity ratio of 10.15, a current ratio of 2.29 and a quick ratio of 2.08.

Harrow (NASDAQ:HROW) last announced its quarterly earnings data on Monday, November 9th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.19 by $0.06. The company had revenue of $99.30 million for the quarter, compared to the consensus estimate of $98.59 million. Harrow had a negative net margin of 9.39% and a negative return on equity of 69.81%. Sell-side analysts predict that Harrow will post -0.02 earnings per share for the current fiscal year.

Insider Activity at Harrow

In other news, insider Amir Shojaei sold 11,250 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $40.00, for a total transaction of $450,000.00. Following the completion of the sale, the insider owned 11,250 shares of the company’s stock, valued at $450,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 12.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Harrow

Institutional investors have recently made changes to their positions in the business. KBC Group NV bought a new position in Harrow in the first quarter worth approximately $31,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Harrow by 15.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 6,840 shares of the company’s stock worth $215,000 after purchasing an additional 908 shares in the last quarter. Sterling Capital Management LLC raised its holdings in Harrow by 836.8% in the 3rd quarter. Sterling Capital Management LLC now owns 1,068 shares of the company’s stock worth $33,000 after purchasing an additional 954 shares during the period. First Bancorp Inc ME bought a new position in Harrow in the 2nd quarter worth $64,000. Finally, State of Wyoming bought a new position in Harrow in the 2nd quarter worth $72,000. Institutional investors own 72.76% of the company’s stock.

Trending Headlines about Harrow

Investors following HROW have been watching these headlines:

• Positive Sentiment: Harrow forecast fourth-quarter revenue of approximately $136 million to $151 million and full-year 2026 revenue of $350 million to $365 million, above the roughly $349.7 million consensus estimate. It also described record third-quarter sales for its eye-care products. Harrow revenue and EBITDA outlook
• Positive Sentiment: BTIG Research reaffirmed its Buy rating and set a $63 price target, signaling substantial upside in the analyst’s view. BTIG Research ratings
• Neutral Sentiment: The company reset its 2026 adjusted EBITDA outlook to more than $40 million. The report provided no prior figure for comparison, so the direction of the change—and its effect on expectations—is unclear.

Harrow Company Profile

Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.